Sinovac Life Sciences has secured around US$500 million in funding to grow, expand capability and produce its COVID-19 vaccine candidate, CoronaVac...
China's "high risk" professionals have been vaccinated with experimental COVID-19 vaccines since July. The Chinese National Health Commission revealed earlier this week these professionals include medical professionals working on the front lines and border officials.
Sinovac, a Beijing-based company producing a vaccine for COVID-19 today announced their "CoronaVac" vaccine concluded preliminary Phase I/II trials showing "favorable immunogenicity and safety profiles."
The South China Morning Post reported today some vaccines may become available as early as this autumn. Pfizer, meanwhile hinted their vaccine could come as early as October of this year.
CanSino Biologics became known to the wider public for being the first manufacturer to begin work on a COVID-19 vaccine back in mid-March.
For key manufacturers, numbers are beginning to reflect the potential financial impact of vaccine development. Hopeful investors have surged the price of Moderna, whose press releases are dominating the news on vaccine development in the US. Recently....
The two groups, The Beijing Institute of Biological Products and China National Biotec Group Co., are producing five variants of the vaccine with an estimated output of 100-120M vaccines per year.